TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33763741
Drug: Continuous local
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous local anaesthetic wound infusion
Study: 32144911
Drug: Acupoint thread-embedding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint thread-embedding therapy at 7-day intervals (Treatment Group 1)
Study: 32144911
Drug: Acupoint thread-embedding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint thread-embedding therapy at 14-day intervals (Treatment Group 2)
Study: 32144911
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between Treatment Group 1 and Treatment Group 2
Study: 34329456
Drug: Recreational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recreational therapy program (3 sessions a week for 2 weeks)
Study: 34329456
Drug: Routine daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine daily activities
Study: 33034357
Drug: High myopic
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High myopic treatment with LASIK
Study: 33684015
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy (upper limb fascial therapy, 50 min weekly session for three weeks)
Study: 32415802
Drug: Canagliflozin 100
Normalized name: canagliflozin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canagliflozin 100 mg daily for 12 weeks
Study: 35533200
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of the noradrenaline reuptake inhibitor atomoxetine
Study: 33131470
Drug: Proactive anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proactive anti-inflammatory therapy combined with anticoagulation
Study: 33128492
Drug: Propranolol 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 1% cream
Study: 33128492
Drug: Timolol 0.5%
Normalized name: Timolol 0.5% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol 0.5% cream
Study: 34864993
Drug: Endometrial scratch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endometrial scratch prior to the second IVF/ICSI treatment
Study: 32931708
Drug: bovine lactoferrin
Normalized name: Bovine lactoferrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: bovine lactoferrin (bLF) 200 mg·(kg body mass)‐1·day‐1
Study: 35921506
Drug: Pramipexole (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole (0.75 mg twice daily, n = 100)
Study: 33423364
Drug: Fludora® Fusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludora® Fusion 562.5 WP-SB (target dose 225 mg AI/m2)
Study: 33423364
Drug: Clothianidin 70
Normalized name: CLOTHIANIDIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clothianidin 70 WG (target dose 200 mg AI/m2)
Study: 33423364
Drug: K-Othrine 250
Normalized name: potassium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: K-Othrine 250 WG (deltamethrin, target dose 25 mg AI/m2)
Study: 33423364
Drug: Ficam VC
Normalized name: Zicam Cough
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ficam VC 80 WP-SB (bendiocarb, target dose 400 mg AI/m2)
Study: 35291435
Drug: Atorvastatin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin with vitamin E (20 mg atorvastatin and 400 IU vitamin E daily for 12 weeks)
Study: 35291435
Drug: Atorvastatin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin with placebo (20 mg atorvastatin daily for 12 weeks)
Study: 35291435
Drug: Atorvastatin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin with vitamin E
Study: 32146550
Drug: Metformin 1000
Normalized name: metformin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1000 mg three times daily (tds) in combination with carboplatin/paclitaxel
Study: 32146550
Drug: Metformin 1000
Normalized name: metformin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1000 mg tds
Study: 34417416
Drug: Supervised group‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised group‐based multicomponent exercise program intervention with oral nutritional supplementation (OEP+N)
Study: 33988924
Drug: Paliperidone Palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone Palmitate once-monthly (PP1M)
Study: 33988924
Drug: Oral Antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Antipsychotics (OAPs)
Study: 32894625
Drug: Standard eradication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard eradication triple therapy
Study: 35849455
Drug: LNG 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNG 1.5 mg
Study: 35849455
Drug: LNG 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNG 3.0 mg
Study: 32643500
Drug: Standard G-CSF
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard G-CSF administration (24 hours after chemotherapy)
Study: 32643500
Drug: Delayed G-CSF
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed G-CSF administration (on the day ANC dropped below 1,000/mm3)
Study: 32643500
Drug: Delayed G-CSF
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed G-CSF administration
Study: 32643500
Drug: Standard G-CSF
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard G-CSF administration
Study: 34684661
Drug: OMEGA group
Approvals — FDA: no, EMA: no, PMDA: no
Description: OMEGA group (20 mL daily dose of dietary formula containing omega-3 and omega-6 PUFAs, vitamin A, vitamin E, and γ-tocopherol)
Study: 34684661
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (20 mL placebo containing virgin olive oil)
Study: 32911210
Drug: Mindfulness‐based Stress
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness‐based Stress Reduction program (90-95 minutes, twice a week for 12 weeks)
Study: 35843540
Drug: Wheat germ
Normalized name: Wheat Germ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat germ (40 g)
Study: 32737004
Drug: NEXIRI (Irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: NEXIRI (Irinotecan 120-180 mg/m2 intravenous on days 1 and 15 plus oral Sorafenib 400 mg twice a day)
Study: 32737004
Drug: IRI (Irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: IRI (Irinotecan 180 mg/m2)
Study: 33480852
Drug: Smartphone app-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smartphone app-based intervention used for 28 days offering daily activities based on 10 recommendations to promote positive mental health.
Study: 36746171
Drug: Secukinumab 300
Normalized name: secukinumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 300 mg every 4 weeks
Study: 34763441
Drug: Manual injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual injection of contrast (N group, n=50)
Study: 34763441
Drug: Gravity drip
Normalized name: DRIP COLLECTOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gravity drip administration of contrast media (O group, n=50)
Study: 35366928
Drug: Ludangshen oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ludangshen oral liquid
Study: 35608396
Drug: PAD bundle
Normalized name: oxymetazoline
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PAD bundle (pain monitoring and management, light sedation and daily awakening, early mobility, sleep promotion, and delirium monitoring)
Study: 34280355
Drug: Icotinib 125
Normalized name: niacin
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icotinib 125 mg thrice daily for 2 years
Study: 34280355
Drug: Chemotherapy (vinorelbine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (vinorelbine and cisplatin or pemetrexed and cisplatin)
Study: 32852646
Drug: Topical tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tacrolimus 0.03% ointment applied once daily for 2–6 months
Study: 33933667
Drug: QUIT intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: QUIT intervention (cognitive behavioral therapy-based, individual weekly counseling sessions targeting anxiety and depressive symptoms)
Study: 33933667
Drug: Time-Matched Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time-Matched Control (TMC) (cognitive behavioral therapy-based, individual weekly counseling sessions)
Study: 32074412
Drug: Antipsychotics treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotics treatment
Study: 36333896
Drug: Albendazole (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (15 mg/kg/day) for 14 days
Study: 33285733
Drug: Danlou tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danlou tablet (1.5 mg a time, 3 times daily for 28 days)
Study: 34961754
Drug: Supervised exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised exercise intervention during chemotherapy (n = 173)
Study: 32808656
Drug: Sparse additive
Normalized name: sparsentan
DrugBank: Sparsentan (DB12548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sparse additive model for treatment effect modification
Study: 32697104
Drug: Intensive outpatient
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive outpatient psychosocial treatment (18-week cognitive-behavioral treatment, two 90-min sessions per week)
Study: 32697104
Drug: Intensive outpatient
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive outpatient psychosocial treatment
Study: 35286322
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapy (SMT) plus rifaximin
Study: 33939512
Drug: Email-only treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Email-only treatment
Study: 33939512
Drug: Mail-plus-email treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mail-plus-email treatment
Study: 36209240
Drug: Montreal Cognitive
Normalized name: BCG, live, Montreal strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montreal Cognitive Assessment (MoCA) administered via telephone
Study: 36233454
Drug: Sufficient fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sufficient fentanyl (maximum estimated effect site concentration: 7.86 ng/mL)
Study: 36233454
Drug: Minimum fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Minimum fentanyl (maximum estimated effect site concentration: 1.5 ng/mL)
Study: 35134703
Drug: Guided internet‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided internet‐based self‐help problem solving therapy intervention
Study: 34246457
Drug: Homeopathic molecule
Normalized name: Urtica urens homeopathic preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathic molecule for nausea and vomiting prevention during chemotherapy
Study: 36302537
Drug: Colchicine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (1.5 mg loading dose, followed by 0.5 mg b.i.d. for 6 days and 0.5 mg q.d. for the second week)
Study: 32641154
Drug: Baricitinib 4
Normalized name: baricitinib 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib 4 mg orally once daily (OD) on days 1‐14 or until discharge; reduced to 2 mg OD for patients aged >75 years or with creatinine clearance of 30‐60 ml/min.
Study: 32641154
Drug: Ravulizumab administered
Normalized name: ravulizumab
DrugBank: Ravulizumab (DB11580)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ravulizumab administered intravenously once according to licensed weight‐based dosing regimen.
Study: 32165251
Drug: OCA 5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCA 5-10 mg
Study: 32165251
Drug: OCA 1.5-3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCA 1.5-3.0 mg
Study: 35365239
Drug: Low-dose DW-MSC
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose DW-MSC (5.0×10^7 cells)
Study: 35365239
Drug: High-dose DW-MSC
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose DW-MSC (1.0×10^8 cells)
Study: 35946280
Drug: Chromium picolinate
Normalized name: Chromium Picolinate
DrugBank: Chromium picolinate (DB11255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chromium picolinate supplementation (400 μg daily for 12 weeks)
Study: 34907435
Drug: Metformin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (0.5 g three times daily)
Study: 32972733
Drug: OS‐IUI treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: OS‐IUI treatment cycles
Study: 33730517
Drug: 0.3 g·kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 g·kg‐1 body mass sodium bicarbonate (NaHCO3)
Study: 33730517
Drug: 0.03 g·kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03 g·kg‐1 body mass sodium chloride (PLA)
Study: 34514494
Drug: Initial invasive
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial invasive treatment (INV)
Study: 34514494
Drug: Initial conservative
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial conservative treatment (CON)
Study: 33386335
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (100,000 IU) with dietary calcium intake >300 mg/day
Study: 33386335
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with dietary calcium intake >300 mg/day
Study: 35672703
Drug: Intermittent screening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent screening and treatment (ISTi)
Study: 32493693
Drug: Oral roxadustat
Normalized name: roxadustat
DrugBank: Roxadustat (DB04847)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Oral roxadustat three times weekly
Study: 32493693
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa injections once weekly
Study: 32290490
Drug: Concurrent Training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent Training (Zumba Fitness® + muscle-strengthening workout)
Study: 34019431
Drug: Carboplatin HIPEC
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin HIPEC (800 mg/m2 for 90 minutes)
Study: 33259451
Drug: Iron isomaltoside
Normalized name: Iron isomaltoside 1000
DrugBank: Iron isomaltoside 1000 (DB12208)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron isomaltoside administered intravenously over 30 minutes during surgical wound closure
Study: 33259451
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered intravenously over 30 minutes during surgical wound closure
Study: 36054180
Drug: High IRSA
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High IRSA (UNa 19-40 mmol/L)
Study: 36054180
Drug: Intermediate IRSA
Normalized name: Prevotella intermedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate IRSA (UNa 41-68 mmol/L)
Study: 36054180
Drug: Low IRSA
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low IRSA (UNa 69-139 mmol/L)
Study: 34406271
Drug: One leg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: One leg, twice a week TENS application
Study: 34406271
Drug: Two legs,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two legs, twice a week TENS application
Study: 35347555
Drug: Curcumin supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin supplementation (2.5 g of turmeric 3×/week for 12 weeks)
Study: 34651206
Drug: 30 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 µg I/kg/day of iodine in oral drops given to 47 infants from their first day of life until hospital discharge
Study: 34651206
Drug: Control group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group: 47 infants without supplements
Study: 33675048
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy (ACT), 8 sessions, 90 minutes each
Study: 33504496
Drug: Liraglutide up
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liraglutide up to 1.8 mg/day
Study: 33276768
Drug: Perioperative cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative cognitive behavioral therapy (CBT) - six individual sessions, two before and four after surgery.
Study: 32920973
Drug: Refined rapeseed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Refined rapeseed oil (RA) 50 g daily for 8 weeks
Study: 32920973
Drug: Refined olive
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Refined olive oil (OL) 50 g daily for 8 weeks
Study: 36268379
Drug: 0.3 μg/kg/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 μg/kg/min remifentanil
Study: 36268379
Drug: 0.1 μg/kg/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 μg/kg/min remifentanil
Study: 34711182
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of text and phone calls with trained advocates
Study: 33568118
Drug: 6-week psychosocial
Normalized name: perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 6-week psychosocial support program with oral health educational components
Study: 32988519
Drug: Chitosan oligosaccharide
Normalized name: chitosan oligosaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chitosan oligosaccharide (COS) supplementation at 200 mg/kg
Study: 34803023
Drug: Antibiotics prior
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics prior to skin incision
Study: 34803023
Drug: Antibiotics after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics after umbilical cord clamping
Study: 33373036
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg/day for six months
Study: 32883567
Drug: Empagliflozin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin (10 mg/day, n = 31)
Study: 32883567
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (n = 18)
Study: 34020345
Drug: Adjunctive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive therapy (Flunarizine) on standardized IS treatment
Study: 33685898
Drug: Biapenem 250
Normalized name: biapenem
DrugBank: Biapenem (DB13028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biapenem 250 mg
Study: 33685898
Drug: Biapenem 1250
Normalized name: biapenem
DrugBank: Biapenem (DB13028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biapenem 1250 mg
Study: 33685898
Drug: Biapenem 1000
Normalized name: biapenem
DrugBank: Biapenem (DB13028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biapenem 1000 mg
Study: 32367561
Drug: Immediate periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate periodontal therapy (oral hygiene instructions and single-visit scaling and root planing)
Study: 32367561
Drug: Delayed periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delayed periodontal treatment (control group)
Study: 34420834
Drug: Zonisamide 50
Normalized name: zonisamide 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zonisamide 50 mg/day (flexible dosing)
Study: 33600189
Drug: l-homocysteine aptamer
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-homocysteine aptamer (randomized SELEX)
Study: 33600189
Drug: l-homocysteine selection
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-homocysteine selection (redirected SELEX)
Study: 32980764
Drug: Hyperbaric ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric ropivacaine (9.5, 11, 12.5, 14, or 15.5 mg)
Study: 34980198
Drug: Sildenafil (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (25 mg orally three times a day for seven days)
Study: 34980198
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical capsules, same dosage and duration)
Study: 36342059
Drug: Mindfulness therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness therapy (8-week face-to-face group program)
Study: 34404324
Drug: Neural mobilization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neural mobilization through mirror therapy (MT)
Study: 32758384
Drug: early parenteral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: early parenteral nutrition (early-PN)
Study: 32758384
Drug: late parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: late parenteral nutrition (late-PN)
Study: 33444161
Drug: Insulin Glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin Glargine 300 units · mL-1 (Gla-300)
Study: 33444161
Drug: Insulin Degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin Degludec 100 units · mL-1 (Deg-100)
Study: 35643381
Drug: Shen-Yuan-Dan (SYD)
Normalized name: Ren shen
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shen-Yuan-Dan (SYD) capsules (4 capsules, 3 times a day, with a further 4 capsules 2 hours before PCI)
Study: 35643381
Drug: Shen-Yuan-Dan (SYD)
Normalized name: Ren shen
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shen-Yuan-Dan (SYD) capsules
Study: 32794482
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy (triple therapy + colloidal bismuth subcitrate)
Study: 32794482
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (amoxicillin, clarithromycin, and omeprazole)
Study: 32307124
Drug: Counseling intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Counseling intervention implemented at the hospital level for medication storage
Study: 32307124
Drug: Counseling intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Counseling intervention for medication storage after adjusting for time
Study: 36124653
Drug: Hydrogen inhalation
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrogen inhalation and hydrogen dissolved in water
Study: 36124653
Drug: Placebo air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo air inhalation
Study: 32109880
Drug: Frequent carbohydrate
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frequent carbohydrate ingestion (15 × 5 g every 5 min)